论文部分内容阅读
目的探讨碳酸酐酶9(carbonic anhydrase 9,CA9)在肾透明细胞癌组织中表达程度与疾病预后之间的相关性。方法收集军事医学科学院附属医院泌尿外科2011年9月~2014年1月接受手术的53例肾透明细胞癌患者术后癌组织标本,并对患者进行随访,统计患者肿瘤复发情况与无疾病生存率(DFS)。通过免疫组化检测石蜡切片中CA9的表达并将其与随访结果进行整合分析。结果在随访53例肾透明细胞癌患者中,11例非转移性肾癌患者术后出现了复发病灶,DFS最长为22个月,最短为4个月,中位DFS为10个月。肿瘤复发组与对照组的免疫组化图像累积光密度值(IOD)分别为230 879.84±64 878.72和444 993.31±146 946.27,差异具有统计学意义(P<0.01)。结论肾透明细胞癌组织中CA9的低表达可能与疾病不良预后相关,可作为判断肾癌预后的指标。
Objective To investigate the relationship between the expression of carbonic anhydrase 9 (CA9) in renal clear cell carcinoma and the prognosis of the disease. Methods Fifty-three patients with clear cell renal cell carcinoma who underwent surgery from September 2011 to January 2014 were enrolled in this study. The postoperative cancer tissues were collected and followed up. The recurrence rate and disease-free survival rate (DFS). The expression of CA9 in paraffin sections was detected by immunohistochemistry and integrated with the follow-up results. Results Of the 53 patients with renal clear cell carcinoma who were followed up, 11 patients with non-metastatic renal cell carcinoma developed recurrent lesions. The DFS was the longest, with a minimum of 4 months and a median DFS of 10 months. The cumulative optical density (IOD) values of immunohistochemical images in tumor recurrence group and control group were 230 879.84 ± 64 878.72 and 444 993.31 ± 146 946.27, respectively, with statistical significance (P <0.01). Conclusions The low expression of CA9 in renal clear cell carcinoma may be related to the poor prognosis of disease, which can be used as an index to judge the prognosis of renal cell carcinoma.